Potential of Mirabegron and its Extended-release Formulations for the Treatment of Overactive Bladder Syndrome

被引:5
作者
Mandpe, Pankaj [1 ]
Pralhakar, Bala [1 ]
Shende, Pravin [1 ]
机构
[1] STKMS NMIMS, Shohhahen Prataphai Patel Sch Pharm & Technol Man, VL Mehta Rd, Mumbai, Maharashtra, India
关键词
Mirabegron; antimuscarinics; overactive bladder; modified release; mechanism; pharmacokinetic; BETA(3)-ADRENOCEPTOR AGONIST; URINARY-INCONTINENCE; MECHANISM; EFFICACY; PHARMACOKINETICS; SOLIFENACIN; METABOLISM; THERAPY; SAFETY;
D O I
10.2174/1389200221666200425211139
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Overactive bladder syndrome is a broadly occurring urological disorder with a distressing impact on the quality of life. The commonly used antimuscarinic drugs show poor patient compliance because of unsatisfactory potency, tolerability and high occurrence of adverse effects such as dry mouth, blurred vision, constipation, dizziness etc. Mirabegron is the first approved beta(3)-adrenoreceptor agonist, used as mono or in combination therapies for overactive bladder syndrome. Objective: The present review provides an insight into the mechanism, pharmacokinetics, toxicokinetics, clinical trials and the development of various conventional and modified-release dosage forms of mirabegron for the treatment of overactive bladder syndrome. Results: The clinical trials of phase II and phase III of mirabegron demonstrated symptomatic relief from the overactive bladder without disturbing the micturition cycle. To date, mirabegron showed promising results for safety, tolerability and efficacy in patients with overactive bladder syndrome. The modified-release tablet dosage form of mirabegron appear to be a proficient and suitable replacement for antimuscarinics and revealed the tremendous potential to overcome the adverse effects of conventional antimuscarinic drugs like Oxybutyline chloride ER, Detrol LA, ESIcare, etc. Conclusion: Mirabegron shows a distinct mode of action, i.e., targeting beta(3)-adrenoreceptors and improving bladder storage without altering void contractions. The limited side effects, high safety, efficacy and tolerability of mirabegron present an adequate substitute to antimuscarinics. However, long-term analysis and clinical studies are prerequisites for assessing the safety, tolerability and efficacy profile of mirabegron.
引用
收藏
页码:79 / 88
页数:10
相关论文
共 62 条
[1]   Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom [J].
Aballea, Samuel ;
Maman, Khaled ;
Thokagevistk, Katia ;
Nazir, Jameel ;
Odeyemi, Isaac A. O. ;
Hakimi, Zalmai ;
Garnham, Andy ;
Toumi, Mondher .
CLINICAL DRUG INVESTIGATION, 2015, 35 (02) :83-93
[2]   Describing bladder storage function: Overactive bladder syndrome and detrusor overactivity [J].
Abrams, P .
UROLOGY, 2003, 62 (5B) :28-37
[3]   Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony) [J].
Abrams, Paul ;
Kelleher, Con ;
Staskin, David ;
Rechberger, Tomasz ;
Kay, Richard ;
Martina, Reynaldo ;
Newgreen, Donald ;
Paireddy, Asha ;
van Maanen, Rob ;
Ridder, Arwin .
EUROPEAN UROLOGY, 2015, 67 (03) :577-588
[4]   Mirabegron relaxes urethral smooth muscle by a dual mechanism involving 3-adrenoceptor activation and 1-adrenoceptor blockade [J].
Alexandre, E. C. ;
Kiguti, L. R. ;
Calmasini, F. B. ;
Silva, F. H. ;
da Silva, K. P. ;
Ferreira, R. ;
Ribeiro, C. A. ;
Monica, F. Z. ;
Pupo, A. S. ;
Antunes, E. .
BRITISH JOURNAL OF PHARMACOLOGY, 2016, 173 (03) :415-428
[5]   On the Site and Mechanism of Action of β3-Adrenoceptor Agonists in the Bladder [J].
Andersson, Karl Erik .
INTERNATIONAL NEUROUROLOGY JOURNAL, 2017, 21 (01) :6-11
[6]  
[Anonymous], 2014, Australian Public Assessment Report for sofosbuvir
[7]  
Augsburger L.L., 2017, PHARM DOSAGE FORMS, DOI [10.1201/9781315111896, DOI 10.1201/9781315111896]
[8]   The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial [J].
Batista, Jose E. ;
Koelbl, Heinz ;
Herschorn, Sender ;
Rechberger, Tomasz ;
Cambronero, Javier ;
Halaska, Michael ;
Coppell, Alex ;
Kaper, Mathilde ;
Huang, Moses ;
Siddiqui, Emad .
THERAPEUTIC ADVANCES IN UROLOGY, 2015, 7 (04) :167-179
[9]  
Beijing Boze Derun Pharmaceutical Technology Development Co. Ltd, 2015, Chinese Patent, Patent No. 104288117
[10]  
Beijing Rundekang Pharmaceutical Technology Co. Ltd, 2014, Merariveron sustained-release tablet and preparation method thereof Chinese Pat- ent, Patent No. 103655503